These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8448973)

  • 1. Optimising ACE inhibitor therapy of congestive heart failure. Insights from pharmacodynamic studies.
    Cody RJ
    Clin Pharmacokinet; 1993 Jan; 24(1):59-70. PubMed ID: 8448973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of angiotensin-converting enzyme inhibitors as a guide to their use in congestive heart failure.
    Cody RJ
    Am J Cardiol; 1990 Oct; 66(11):7D-11D; discussion 11D-13D. PubMed ID: 2220605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic drug interactions with ACE inhibitors.
    Shionoiri H
    Clin Pharmacokinet; 1993 Jul; 25(1):20-58. PubMed ID: 8354016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
    Burnier M; Biollaz J
    Clin Pharmacokinet; 1992 May; 22(5):375-84. PubMed ID: 1505143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal angiotensin-converting enzyme inhibitor dose in heart failure?
    Thomas S; Geltman E
    Congest Heart Fail; 2006; 12(4):213-8. PubMed ID: 16894280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relations between pharmacokinetics and effectiveness of ACE inhibitors].
    Rettig R; Gohlke P; Unger T
    Z Kardiol; 1991; 80 Suppl 2():16-20. PubMed ID: 2024539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitors in mild heart failure: first-line or second-line therapy?
    Cleland JG
    Eur Heart J; 1990 May; 11 Suppl D():53-7. PubMed ID: 2193811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
    J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure.
    Reyes AJ
    Am J Cardiol; 1995 Jun; 75(18):50F-55F. PubMed ID: 7778535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure.
    Gottlieb SS; Weir MR
    Am J Cardiol; 1990 Oct; 66(11):14D-20D; discussion 20D-21D. PubMed ID: 2220600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ACE inhibition in heart failure and compromised kidney function].
    Drexler H
    Klin Wochenschr; 1991; 69 Suppl 24():59-64. PubMed ID: 1865634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Side effects of vasodilator therapy in heart failure: risk of hypotension with ACE inhibitors].
    Kromer EP; Elsner D; Riegger GA
    Z Kardiol; 1991; 80 Suppl 2():11-5. PubMed ID: 2024538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure.
    Suki WN
    Arch Intern Med; 1989 Mar; 149(3):669-73. PubMed ID: 2537612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.